2024-03-29T10:42:32Zhttp://repisalud.isciii.es/oai/requestoai:repisalud.isciii.es:20.500.12105/93412024-02-10T18:46:31Zcom_20.500.12105_15322com_20.500.12105_2051com_20.500.12105_2174com_20.500.12105_2173col_20.500.12105_16927col_20.500.12105_2175
00925njm 22002777a 4500
dc
Cattrini, Carlo
author
Castro, Elena
author
Lozano, Rebeca
author
Zanardi, Elisa
author
Rubagotti, Alessandra
author
Boccardo, Francesco
author
Olmos, David
author
2019-09-12
The possible treatments options for metastatic hormone-sensitive prostate cancer (mHSPC) have dramatically increased during the last years. The old backbone, which androgen-deprivation therapy (ADT) is the exclusive approach for hormone-naïve patients, has been disrupted. Despite the fact that several high-quality, randomized, controlled phase 3 trials have been conducted in this setting, no direct comparison is currently available among the different strategies. Inadequate power, absence of preplanning and small sample size frequently affect the subgroup analyses according to disease volume or patient's risk. The choice between ADT alone and ADT combined with docetaxel, abiraterone acetate, enzalutamide, apalutamide or radiotherapy to the primary tumor remains challenging. Factors that are related to the tumor, patient or drug side effects, currently guide these clinical decisions. This comprehensive review aims to indirectly compare the phase 3 trials in the mHSPC setting, in order to extrapolate data useful for treatment selection, providing also perspectives on future biomarkers.
Cancers (Basel). 2019 ;11(9). pii: E1355
2072-6694
http://hdl.handle.net/10668/14537
http://hdl.handle.net/20.500.12105/9341
31547436
10.3390/cancers11091355
Cancers
abiraterone acetate
apalutamide
docetaxel
enzalutamide
hormone-naïve prostate cancer
hormone-sensitive prostate cancer
radiotherapy
Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer